RxDoctor Payments Data

Ari Bunim, MD

Gastroenterology · Flushing, NYNPI 1386707933

Payments from drug & device makers

$296,674in general payments, 2019–2025

Across 815 payments — averaging $364.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$97K
  • Gilead$82K
  • AbbVie$76K
  • Novo Nordisk$16K
  • Intercept Pharmaceuticals, Inc.$15K
  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • plus $7K from 23 others

What the payments were for

  • Consulting fees$11,1354%
  • Speaking & faculty fees$245,99483%
  • Travel & lodging$23,4958%
  • Food & beverage$16,0435%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$296,674 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$125,121
Medicare patients
464
Services billed
891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab16$443,952
XifaxanRifaximin32$105,428
RinvoqUpadacitinib11$72,350
CreonLipase/Protease/Amylase29$69,765
LinzessLinaclotide68$43,735
TrulancePlecanatide18$11,864
Mesalamine ErMesalamine36$8,517
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates126$7,848
Ursodiol62$7,115
Budesonide EcBudesonide27$5,190
Mesalamine20$4,872
Budesonide DrBudesonide21$2,511
Lubiprostone16$2,407
Pantoprazole Sodium270$2,313
Dexlansoprazole DrDexlansoprazole12$1,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$149$443,95216 claims
AbbVieRinvoq, Creon, Linzess$76,057$185,850108 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,523$117,29250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →